IBS-d Clinical Trial

We understand IBS-d.

We’re running a low-commitment clinical trial to examine a potential new natural treatment for IBS-d.

Irritable Bowel Syndrome – Diarrhea (IBS-d) is a bowel movement disorder characterized by chronic abdominal pain and diarrhea. Although 15% of the general population reports symptoms, there is currently no approved medication to treat the condition. If you’re reading this though, you probably already knew that.

What you don’t know is that we are holding a clinical study for a potential natural treatment that may relieve IBS-d symptoms. We are comparing the effects of our treatment to those of a placebo on patients’ bowel movements, reported stool frequency, and severity of IBS-d symptoms. Those suffering from IBS-Constipation (or alternating IBS-C and IBS-D) are not eligible for the trial.

What are we asking of you?

  • Visit the Clinical Investigation Unit five times
  • Take capsules daily as directed
  • Track your daily intake and symptoms

The study requires five (5) visits to the Clinical Investigation Unit (CIU) located at the University of Alberta Hospital over a 12-week period. We will assign you to either the treatment group or the placebo group, and you’ll need to take your capsules as directed.

You’ll be asked to record your daily IBS-d symptoms. You’ll also be asked to reduce your sugar intake, avoid known trigger foods, and avoid processed foods wherever possible for the duration of the trial.

We will assess your compliance with the study, any upper GI symptoms, your quality of life, any adverse reactions, and your use of non-study medication.

When the study is complete, we will have a better understanding of how IBS-d works, how we can effectively treat it, and how treatment can improve quality of life for IBS-d patients like you.

×

Find out if you're eligible.

Please answer the questions below as accurately as you can. If you meet the study conditions, we'll contact you about participating.

Your personal information will be kept confidential, will only be used to determine your eligibility for the clinical trial, and will not be sold or shared with third-party businesses or organizations.

`